Variations in treatment organization, practices and outcomes within the Norwegian Opioid Maintenance Treatment Programme

Norsk Epidemiologi

Volumn 21, Issue 1, 2011, Pages 113-118

  Gjersing, Linn ^a   Waal, Helge ^a   Røislien, Jo ^a   Gossop, Michael ^a,b   Clausen, Thomas ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG PREFERENCE; DRUG USE; FEMALE; GOVERNMENT REGULATION; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE PRACTICE; HEALTH PROGRAM; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NORWAY; OPIATE ADDICTION; OUTCOME ASSESSMENT; PRESCRIPTION; PSYCHOSOCIAL REHABILITATION; SOCIAL SECURITY; TREATMENT RESPONSE; UNEMPLOYMENT;

EID: 84855799154     PISSN: 08032491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Ball JC, Ross A. The effectivness of methadone maintenance treatment. New York: Springer, 1991.
2. Clausen T, Anchersen K, Waal H. Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 2008; 94 (1-3): 151-7.
3. Stewart D, Gossop M, Marsden J. Methadone treatment: outcomes and variation in treatment response within NTORS. In: Strang J, Tober G, eds. Methadone matters evolving community methadone treatment of opiate addiction. London: Martin Dunitz, 2003: 249-91.
4. Caplehorn JR. A comparison of abstinence-oriented and indefinite methadone maintenance treatment. Int J Addict 1994; 29 (11): 1361-75.
5. Pollack HA, D'Aunno T. Dosage patterns in methadone treatment: results from a national survey, 1988-2005. Health Serv Res 2008; 43 (6): 2143-63.
6. Winstock AR, Lea T, Sheridan J. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia. Int J Drug Policy 2008; 19 (6): 450-8.
7. Dole VP, Nyswander ME. Rehabilitation of heroin addicts after blockade with methadone. N Y State J Med 1966; 66 (15): 2011-7.
8. Gossop M, Stewart D, Marsden J. Treatment process components and heroin use outcome among methadone patients. Drug Alcohol Depend 2003; 71 (1): 93-102.
9. D'Aunno T. The role of organization and management in substance abuse treatment: Review and roadmap. J Subst Abuse Treat 2006; 31 (3): 221-33.
10. Gossop M, Grant M. Six country survey of the content and structure of heroin treatment programmes using methadone. Br J Addict 1991; 86 (9): 1151-60.
11. Stewart D, Gossop M, Marsden J, Strang J. Variation between and within drug treatment modalities: data from the National Treatment Outcome Research Study (UK). Eur Addict Res 2000; 6 (3): 106-14.
12. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence: A randomized trial. JAMA 1999; 281 (11): 1000-5.
13. Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a metha-done maintenance treatment (MMT) clinic in Israel. Drug Alcohol Depend 2006; 82 (3): 211-7.
14. Liu E, Liang T, Shen L, Zhong H, Wang B, Wu Z, et al. Correlates of methadone client retention: A prospective cohort study in Guizhou province, China. Int J Drug Policy 2009; 20 (4): 304-8.
15. Woodward AM, Raskin IE, Blacklow B. A profile of the substance abuse treatment industry: organization, costs, and treatment completion. Substance Use Misuse 2008; 43 (5): 647-79.
16. Broome KM, Flynn PM, Knight DK, Simpson DD. Program structure, staff perceptions, and client engagement in treatment. J Subst Abuse Treat 2007; 33 (2): 149-58.
17. Jaffe JH, O'Keeffe C. From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003; 70 (2 Suppl): S3-S11.
18. Rettig RA, Yarmolinsky A. Federal regulation of methadone treatment. Washington DC: National Academy Press, 1995.
19. Kleber HD. Methadone maintenance 4 decades later: thousands of lives saved but still controversial. JAMA 2008; 300 (19): 2303-5.
20. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med 2000; 67 (5-6): 347-64.
21. EMCDDA. The drug situation in Norway. Lisbon: European monitoring centre for drug and drug addiction (EMCDDA), 2010.
22. Waal H. Merits and problems in high-threshold methadone maintenance treatment. Evaluation of medication-assisted rehabilitation in Norway 1998-2004. Eur Addict Res 2007; 13 (2): 66-73.
23. Waal H, Clausen T, Håseth A, Lillevold PH. The 2007 annual assessment of the Norwegian OMT programme. Oslo: Seraf - Norwegian Centre for Addiction Research, University of Oslo, 2008, Report No 1.
24. Vånar M. Reliability testing of the questionnaire used in the annual OMT assessments. Oslo: Seraf - Norwegian Centre for Addiction Research, University of Oslo, 2005, Report No 1.
25. Preacher KJ, MacCallum RC. Repairing Tom Swift's electric factor analysis machine. Understanding Statistics 2003; 2 (1): 13-43.
26. SPSS Inc. SPSS release 16.0 statistical software [computer program]. Chicago, SPSS Inc., 2008.
27. R Development core team. R: a language and environment for statistical computing [computer program]. Vienna: R Foundation for statistical computing. 2008.
28. Ball JC, Corty E, Petroski SP, Bond H, Tommasello A, Graff H. Medical services provided to 2,394 patients at methadone programs in three states. J Subst Abuse Treat 1986; 3 (3): 203-9.
29. Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29 (3): 214-26.
30. Payte JT. A brief history of methadone in the treatment of opioid dependence: a personal perspective. J Psychoactive Drugs 1991; 23 (2): 103-7.
31. Wehrens R, Bekker M, Bal R. The construction of evidence-based local health policy through partnerships: Research infrastructure, process, and context in the Rotterdam 'Healthy in the City' programme. J Public Health Policy 2010; 31 (4): 447-60.
32. Irwin KS, Fry CL. Strengthening drug policy and practice through ethics engagement: an old challenge for a new harm reduction. Int J Drug Policy 2007; 18 (2): 75-83.